Chambers v. Idaho Board of Pharmacy

516 P.3d 571, 170 Idaho 701
CourtIdaho Supreme Court
DecidedAugust 24, 2022
Docket49356
StatusPublished
Cited by2 cases

This text of 516 P.3d 571 (Chambers v. Idaho Board of Pharmacy) is published on Counsel Stack Legal Research, covering Idaho Supreme Court primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Chambers v. Idaho Board of Pharmacy, 516 P.3d 571, 170 Idaho 701 (Idaho 2022).

Opinion

IN THE SUPREME COURT OF THE STATE OF IDAHO

Docket No. 49356

CINDY A. CHAMBERS, ) ) Petitioner-Appellant, ) Boise, May 2022 Term ) v. ) Opinion filed: August 24, 2022 ) IDAHO BOARD OF PHARMACY AND ) Melanie Gagnepain, Clerk AGENCY, ) ) Respondent. )

Appeal from the District Court of the Fourth Judicial District of the State of Idaho, Ada County. Samuel Hoagland, District Judge.

The judgment of the district court is affirmed.

Bernadette Cecile Buentgen, Eagle, for Appellant. Bernadette Buentgen argued.

Lawrence G. Wasden, Idaho Attorney General, Boise, for Respondent. Alexandra Breshears argued. __________________________________________________________________

MOELLER, Justice. The Idaho Board of Pharmacy (“Board”) filed an administrative complaint against Cindy A. Chambers, a pharmacist, alleging that she dispensed a controlled substance without a valid prescription. Chambers prevailed before the Board and it determined that she was entitled to recover her reasonable attorney fees and costs; however, she failed to comply with the 14-day deadline for requesting her award. When she filed a request almost seven months after the deadline had passed, the Board denied her request upon finding that she failed to show good cause for the late filing. Chambers then sought judicial review from the district court, which dismissed her petition. Chambers now appeals to this Court, maintaining that both the Board and the district court erred by applying the wrong legal standard. For the following reasons, we affirm. I. FACTUAL AND PROCEDURAL BACKGROUND In 2018, Chambers was a pharmacist working at a Sav-On Pharmacy for Albertsons, LLC, in Boise, Idaho. She was the “Pharmacist-in-Charge” at the Boise pharmacy during all times at

1 issue in this case. On September 25, 2018, a Board compliance officer conducted a routine inspection of the Sav-On pharmacy’s records where Chambers is employed. During the audit, the compliance officer found a record showing Chambers had dispensed 50 mg of Tramadol, a Schedule IV medication, on July 14, 2018, without an accompanying valid prescription. Board staff filed an administrative complaint against Chambers, alleging she violated the statutes or rules governing the practice of pharmacy in Idaho by dispensing a controlled substance without a valid prescription. At the hearing before the Board, Chambers presented evidence that she rejected the original Tramadol prescription, written by a veterinarian for a dog, because it lacked the required information, “including, but not limited to, the drug name and strength.” Because of this immediate rejection, the prescription was never scanned into Sav-On’s electronic records system. The dog’s owners subsequently returned to Sav-On with an additional prescription to acquire the medication. However, Chambers rejected the second prescription because it still lacked the necessary information. Chambers testified that she then called the prescribing veterinarian by phone to verbally obtain the necessary information to create a valid prescription. Chambers reduced the verbal prescription to writing and provided it to a pharmacy technician for processing. Chambers then dispensed 50 mg of Tramadol to the dog’s owners. Additional evidence was submitted to show a pharmacy technician had failed to scan the valid prescription into the record-keeping system, but that the veterinarian confirmed that she prescribed the 50 mg of Tramadol to the dog’s owners and that she later verified the prescription with Chambers over the phone. From these findings, the Board concluded “there is no evidence in the record alleging or suggesting any efforts by [Chambers] to divert any drugs.” In its final order, issued on May 6, 2019, the Board concluded that Chambers acted reasonably and dismissed the administrative complaint. The Board also determined that Chambers was entitled to recover attorney fees and costs. The final order did not specify a deadline for requesting attorney fees, but stated: “. . . pursuant to Idaho Code sections 12-117(5) and 54-1728(6), [Chambers] is entitled to recover her reasonable attorney’s fees and defense costs necessarily and actually incurred in this matter, which [Chambers] may apply for in accordance with Rule 741 of the Idaho Rules of Administrative Procedure of the Attorney General (IDAPA 04.11.01.741).” Rule 741, referred to in the final order, generally provides that the time for filing a request for attorney fees awarded by an agency is “(14) days from the service date of the final order” unless

2 the final/preliminary order specifically extends that time. IDAPA 04.11.01.741. Thus, where the time is not specifically set forth in a statute, rules of the agency, or the final order itself, “the deadline for filing for costs and/or fees and/or for moving for an extension of the time to file for costs and fees is fourteen (14) days from the service date of the final order or preliminary order.” IDAPA 04.11.01.741.02(c). Additionally, “[t]he agency may exercise its discretion to consider and grant an untimely filing for costs and/or fees for good cause shown.” IDAPA 04.11.01.741.02(d). The certificate of mailing for the final order indicates it was served on Chambers’ attorney on May 7, 2019, making May 21, 2019, the deadline to file a request for attorney fees. Almost seven months (204 days) later, on December 11, 2019, Chambers filed a request for $6,761.25 in attorney fees through her counsel, Bernadette Buentgen. The Board filed an objection to this request, arguing it was untimely and lacked a showing of good cause to explain the late filing. Buentgen then submitted a second declaration in support of the request for attorney fees, which included detailed information concerning her health status from 2006 forward. In her declaration, Buentgen explained that she was diagnosed with Chronic Myeloid Leukemia 13 years earlier and, following her diagnosis, underwent targeted chemotherapy from 2006 until November 2013. Her daily medications “had numerous side-effects, including overwhelming fatigue.” To reach remission, Buentgen underwent a stem cell transplant in 2014. The procedure was successful but not without complications: Buentgen contracted GVHD (graft vs. host disease), which required additional medications and blood transfusions until 2017. While Buentgen has been “leukemia free for six years,” she reports that she “still [has] a compromised immune system and continues to struggle with fatigue.” She explained in the declaration that her “new normal changes daily” and requires constant reassessments and adjustments. On reviewing this second declaration, the Board informed Buentgen she had again failed to explain any “specific events between May 2019 and December 2019” that “prevented [her] from filing or seeking an extension of time to file.” Buentgen then filed a third declaration in support of the request for attorney fees, which argued her health conditions were good cause and “there [was] no showing of harm or prejudice” to the Board. This third declaration also included information from Buentgen that she “did not calendar the fourteen (14) day deadline,” and “did not anticipate . . . an issue concerning the payment of [her] attorney fees if the bill was presented more than fourteen (14) days after the Final Order.” She conceded, however, that “possibly . . . was a mistake

3 on [her] part.” Additionally, Buentgen explained that she is a solo practitioner without “the resources to hire someone to prepare the statement of attorney fees.” The Board conducted a hearing on the attorney fees matter on April 9, 2020. At the hearing, Buentgen argued that “prejudice is a determining factor in whether good cause is shown.” She explained in full: So the issue here is not whether the Board is awarding attorney’s fees. That’s already been decided.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

York v. Kemper Northwest, Inc.
Idaho Supreme Court, 2026
Roy v. IDHW
Idaho Supreme Court, 2024
Skehan v. ISP
Idaho Supreme Court, 2024

Cite This Page — Counsel Stack

Bluebook (online)
516 P.3d 571, 170 Idaho 701, Counsel Stack Legal Research, https://law.counselstack.com/opinion/chambers-v-idaho-board-of-pharmacy-idaho-2022.